Back to Search Start Over

Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group.

Authors :
Fangusaro J
Witt O
Hernáiz Driever P
Bag AK
de Blank P
Kadom N
Kilburn L
Lober RM
Robison NJ
Fisher MJ
Packer RJ
Young Poussaint T
Papusha L
Avula S
Brandes AA
Bouffet E
Bowers D
Artemov A
Chintagumpala M
Zurakowski D
van den Bent M
Bison B
Yeom KW
Taal W
Warren KE
Source :
The Lancet. Oncology [Lancet Oncol] 2020 Jun; Vol. 21 (6), pp. e305-e316.
Publication Year :
2020

Abstract

Paediatric low-grade gliomas (also known as pLGG) are the most common type of CNS tumours in children. In general, paediatric low-grade gliomas show clinical and biological features that are distinct from adult low-grade gliomas, and the developing paediatric brain is more susceptible to toxic late effects of the tumour and its treatment. Therefore, response assessment in children requires additional considerations compared with the adult Response Assessment in Neuro-Oncology criteria. There are no standardised response criteria in paediatric clinical trials, which makes it more difficult to compare responses across studies. The Response Assessment in Pediatric Neuro-Oncology working group, consisting of an international panel of paediatric and adult neuro-oncologists, clinicians, radiologists, radiation oncologists, and neurosurgeons, was established to address issues and unique challenges in assessing response in children with CNS tumours. We established a subcommittee to develop consensus recommendations for response assessment in paediatric low-grade gliomas. Final recommendations were based on literature review, current practice, and expert opinion of working group members. Consensus recommendations include imaging response assessments, with additional guidelines for visual functional outcomes in patients with optic pathway tumours. As with previous consensus recommendations, these recommendations will need to be validated in prospective clinical trials.<br /> (Copyright © 2020 Elsevier Ltd. All rights reserved.)

Details

Language :
English
ISSN :
1474-5488
Volume :
21
Issue :
6
Database :
MEDLINE
Journal :
The Lancet. Oncology
Publication Type :
Academic Journal
Accession number :
32502457
Full Text :
https://doi.org/10.1016/S1470-2045(20)30064-4